• In the News

    Intarcia Raises Recent Royalty/Equity Conversion Financing Total to
    $300 Million

    Continuing investment demand prompts Company to exercise re-opener adding $75 million. Equity conversion terms still set for $5.5 billion Company valuation.

    Read more


    Intarcia CEO named an EY Entrepreneur Of The Year 2015
    Kurt Graves accepts honor at event in Boston, saying Company's entrepreneurialism is based on its sense of urgency to make a difference for patients.

    Read more

  • Message from the CEO

    Our Partnership in Diabetes Begins with Our Vision for Progress

    Our participation at ADA’s 75th Scientific Sessions in Boston put our vision for progress ‘on the record’ with the broader diabetes community. Now we will work together to determine how best to capture the full clinical and health-economic benefits of our investigational therapy ITCA 650 for patients, providers and payers.

    Read more

  • Two of the FREEDOM Phase 3 clinical trials are now successfully completed: FREEDOM-1 and the FREEDOM-1 HBL studies both met all key clinical endpoints. There are two remaining studies in the overall program: FREEDOM-2 and the FREEDOM-CVO Safety Study.

    Learn more about the FREEDOM Trials ›


  • Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia

    What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"

    Hear Kurt Graves speak on this topic ›